MMED posts 17% Q1 FY27 net sales growth, lifts guidance
MMED reported 17% Q1 FY27 net sales growth and raised full-year organic revenue growth guidance to 10.5%. It also cited an adjusted EBITDA margin of 16%.
Q1 FY27 saw 17% net sales growth, driven by strong U.S. and international performance, new product launches, and pipeline progress.
Guidance for organic revenue growth was raised to 10.5% for FY27, with an adjusted EBITDA margin of 16%.Original document: MiniMed Group, Inc. [MMED] SEC 8-K Current R…